BURLINGTON, Mass.— AlloCure Inc. has named former AMAG Pharmaceuticals executive Robert M. Brenner, MD, as its new president and chief executive officer.
“AlloCure has made great strides in advancing the promise of cell therapy for the preservation of kidney health,” said Brenner. “ I am excited to join the company in this dynamic period and am eager to contribute to fully developing this therapy for the benefit of patients so greatly in need.”
Brenner was previously senior vice president of medical affairs at AMAG Pharmaceuticals, and for nine years was part of Amgen’s global development efforts in nephrology and renal anemia.
AlloCure Inc. is a biotechnology company developing cell therapies for the treatment of kidney diseases. John Wirthlin, AlloCure’s previous CEO, assumes the position of chief operating officer and remains a member of the company’s management team.
Preparing for Phase 2 Trials in acute kidney injury, “Allocure has reached an important milestone in the company’s evolution, with the completion of enrollment in our Phase 1 trial in acute kidney injury,” said Wirthlin. “We look forward to completing this study soon and presenting the results in an appropriate scientific forum. We are now preparing for a Phase 2 study aimed at providing clinical proof-of-concept for our technology.”
“Robert Brenner’s extensive medical background, relationships with the nephrology community, and experience with the strategic development and commercialization of important renal therapeutics will be a major asset for AlloCure as the company advances its novel cell therapy through the clinic and towards commercialization,” said Lutz Giebel, PhD, AlloCure board member and Managing Partner, SV Life Sciences.
“With the expansion of the company’s activities in preparation for Phase 2 clinical trials, we are pleased that John Wirthlin will serve as COO, working closely with Rob on the company’s management team,” said Thomas Dyrberg, Senior Partner, Novo Ventures, Novo A/S.
